secwatch.observer — SEC 8-K summary
======================================

Issuer:     DLH Holdings Corp. (DLHC)
CIK:        0000785557
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0000785557-22-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DLH Q3 revenue $66.4M (+8% YoY), EPS $0.34, operating margin 10.7%
------------------------------------------------------------------

- Revenue $66.4M, up 8% YoY; net income $4.9M vs $2.9M; diluted EPS $0.34 vs $0.21.
- Operating margin improved to 10.7% from 8.0% on higher revenue, better mix, and lower fringe costs.
- Debt reduced to $28.5M from $37.5M at March 31, 2022; total backlog $509.7M.
- Won DoD health R&D IDIQ and NIH National Cancer Institute clinical research contract.
- EBITDA $9.0M (13.5% of revenue) vs $7.0M (11.3%) in prior year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/785557/000078555722000013/0000785557-22-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/785557/000078555722000013/dlhc-20220802.htm
  HTML page:      https://secwatch.observer/filing/0000785557-22-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer